CLINICAL CORE

临床核心

• 批准号: 8092636
• 负责人: Richard J. Caselli
• 金额: $ 76.95万
• 依托单位: BANNER SUN HEALTH RESEARCH INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8092636
• 关键词: Address; Age; Alzheimer' s Disease; Alzheimer' s disease risk; American Indians; Apolipoprotein E; Arizona; Autopsy; Brain; Brain imaging; Catchment Area; Categories; Clinical; Cognitive; Collaborations; Consensus; DNA; Data; Data Set; Dementia; Diagnostic; Diagnostic tests; Early Diagnosis; Eligibility Determination; Enrollment; Funding; Funding Mechanisms; Genetic; Genomics; Genotype; Goals; Health Personnel; Image; Individual; Institution; International; Latino; Longitudinal Studies; Measures; Medical; Minority Groups; Modeling; Native Americans; Neurologic; Neurologist; Participant; Patients; Persons; Prevention; Procedures; Research; Research Methodology; Research Personnel; Research Project Grants; Research Subjects; Resources; Risk Factors; Scientist; Site; Staging; Subgroup; Testing; Tissues; Translational Research; Work; base; clinical Diagnosis; clinical research site; cognitive neuroscience; cohort; cooperative study; data management; follow-up; member; mild neurocognitive impairment; neuroimaging; neuropathology; neuropsychological; normal aging; novel; outreach; outreach program; prevent; programs; symposium; tertiary care; tool; tribal leader; volunteer

The Clinical Core of the Arizona ADCC is a consortium of five recruitment sites that function as a standardized unit under a single Clinical Core Director. The Clinical Core maintains a target of 500 participants at all stages of the aging-dementia spectrum including 200 normal controls, 100 patients with mild cognitive impairment (MCI), and 200 with Alzheimer's disease (AD) and other forms of degenerative dementia. Embedded within these diagnostic categories are defined Latino and Native American cohorts. The Clinical Core capitalizes on our multi-institutional diagnostic consensus conference, centralized data management program, and close working relationships with each of the other Cores. It is intended to capitalize on our multi-institutional collaborative model, address the challenges associated with a multi-site core, and optimize the utilization of Clinical Core subjects and data in support of the unusually early detection and tracking of AD, our strengths in brain imaging, cognitive neuroscience, neurogenomics, our studies of several putative risk factors, and our participation in several national and international collaboration projects. All subjects undergo standardized diagnostic testing that 1) fulfills strict entrance criteria, 2) includes demographic, historical, medical, neurological, psychiatric, neuropsychological, and genetic measures, 3) incorporates the NACC Uniform Data Set (UDS), and 4) employs culturally sensitive test procedures. Patients eligible for enrollment and those completing annual follow-up are discussed in a biweekly diagnostic consensus conference. All undergo apolipoprotein E (APOE) genotyping at entry, and an annual standardized neuropsychological battery of tests at all sites. Patient eligibility for, and participation in ongoing research projects is tracked and reviewed on an ongoing basis. All are offered enrolled in the Brain Donation Program for neuropathological confirmation of clinical diagnoses, though brain donation is not required of members of culturally sensitive diversity subgroups (Latino and Native Americans). The particular strengths of the Clinical Core include: 1. catchment areas throughout the state of Arizona based on a novel collaborative model that includes all major tertiary care referral centers (BNI, MCA, SHRI, VA, UA) 2. a scientific network of established collaborative relationships between Clinical Core neurologists and biomedical researchers at all major research institutions in Arizona (and elsewhere) 3. a Latino outreach program (through the collaborative efforts of the EIT and Clinical Cores) with a target enrollment of at least 100 dementia/MCI patients and controls 4. a Native American outreach program (through the collaborative efforts of the EIT and Clinical Cores) that encourages the participation of Native Americans in the Clinical Core. 5. ancillary programs of longitudinally studied aging normal controls also receive the NACC UDS supported through other funding mechanisms. These cohorts provide unique opportunities to study the transition between cognitive normality and MCI in persons at differential risk for AD and to capitalize on our strengths in imaging, genomics, cognitive neuroscience, and other research methods. To address the goals of the ADCC, subjects and data from independently funded projects are now available as a resource to other researchers, being used in other studies, and will be followed prospectively using the UDS.

亚利桑那州 ADCC 的临床核心是一个由五个招募站点组成的联盟，这些招募站点充当 单一临床核心主任领导下的标准化单位。临床核心维持 500 的目标 老年痴呆症谱系各个阶段的参与者，包括 200 名正常对照者、100 名患有痴呆症的患者 轻度认知障碍 (MCI)，以及 200 名患有阿尔茨海默病 (AD) 和其他形式退行性疾病的患者 失智。这些诊断类别中包含了拉丁裔和美洲原住民群体的定义。 临床核心利用我们的多机构诊断共识会议、集中数据 管理计划，以及与其他每个核心的密切工作关系。其目的是 利用我们的多机构协作模式，解决与多站点相关的挑战 核心，并优化临床核心科目和数据的利用，以支持异常早期的研究 AD 的检测和跟踪，我们在脑成像、认知神经科学、神经基因组学方面的优势，我们的 对几个假定的风险因素的研究，以及我们参与多个国家和国际的研究 合作项目。所有受试者均接受标准化诊断测试，1) 满足严格的入学要求 标准，2) 包括人口统计、历史、医学、神经病学、精神病学、神经心理学和 遗传测量，3) 纳入 NACC 统一数据集 (UDS)，以及 4) 采用文化敏感的 测试程序。符合入组条件的患者和完成年度随访的患者将在 每两周一次的诊断共识会议。所有患者在入境时均接受载脂蛋白 E (APOE) 基因分型，并且 在所有地点进行年度标准化神经心理学测试。患者的资格和参与 持续跟踪和审查正在进行的研究项目。全部都提供注册 用于临床诊断的神经病理学确认的脑捐赠计划，尽管脑捐赠是 对文化敏感的多样性亚群体（拉丁裔和美洲原住民）的成员不要求这样做。这 临床核心的特殊优势包括： 1. 整个亚利桑那州的集水区基于一种新颖的协作模式，其中包括所有 主要三级护理转诊中心（BNI、MCA、SHRI、VA、UA） 2. 临床核心神经科医生和临床核心神经科医生之间建立的合作关系的科学网络 亚利桑那州（和其他地方）所有主要研究机构的生物医学研究人员 3. 拉丁裔外展计划（通过 EIT 和临床核心的协作努力），其目标是 招募至少 100 名痴呆/MCI 患者和对照组 4. 美洲原住民外展计划（通过 EIT 和临床核心的协作努力） 鼓励美洲原住民参与临床核心。 5. 纵向研究衰老正常对照的辅助程序也得到 NACC UDS 支持 通过其他融资机制。这些群体提供了研究转型的独特机会 不同 AD 风险人群的认知正常和 MCI 之间的关系，并利用我们的优势 成像、基因组学、认知神经科学和其他研究方法。为了实现以下目标 ADCC、独立资助项目的主题和数据现在可作为其他资源 研究人员正在将其用于其他研究，并将使用 UDS 进行前瞻性跟踪。